@@

Objective　To investigate the status of apoptosis of osteoblast, osteoclast and the relative factors. Methods　Apoptotic cells were examined using in situ end labeling technique. Expressions of bcl-2, Fas and transforming growth factor(TGF)β1 were observed with immunohistochemical method. Results　Positive expression rate (40.5±5.2)% of apoptosis cells was significantly increased in the osteoblast, but the expression rate of apoptosis cells (8.4±1.2)% was significantly decreased in the osteoclast of the post-ovariectomy rats than in the sham-operated rats. The expression of Fas was decreased in osteoclast (20.0%) and increased in osteoblast (80.0%) of the post-ovariectomized rats. The expression of TGFβ1 was significantly decreased in the osteoclast (0) and the osteoblast (20.0%) of the post-ovariectomized rats. The above-mentioned targets in post-ovariectomized rats treated with nilestriol/levonorgestrel were close to those sham-operated rats (P＞0.05). Conclusions　 Bone loss in the post-ovariectomized rats is attributable to the lower level of estrogen so that the apoptosis cells were decreased in osteoclast but were increased in osteoblast. As a result, the process of bone absorption prevails over that of bone formation. Expression of TGFβ1 depends on stimulation of estrogen. TGFβ1 may stimulate apoptosis of osteoclast and restrain apoptosis of osteoblast. Fas can induce the apoptosis of osteoclast.

Objective To study the expression and significance of CD10, SMA, P63 on human breast myoepithelial cells. Methods SP immunohistochemical method was used to examine the expression of CD10, SMA, P63 on human breast myoepithelial cells from 68 breast diseases samples, including breast fibroadenoma, breast fibroadenesis, breast atypical ductal hyperplasias, ductal carcinomas in situ and breast invasive carcinomas. Results 2 +/3 + circumferential CD10, SMA and P63 staining of MEC was seen in 10 patients with breast fibroadenoma, breast fibroadenoma and 13 patients with atypical ductal hyperplasias. In an analysis of total ducts by 15 patients with breast ductal carcinomas in situ, 3 + circumfenrential staining was seen in 92 of 384 ducts(23.96%) stained for CD10 versus 185 of 384 ducts (48. 18%) stained for SMA and 80 of 384 ducts(20. 83%) stained for P63. All differences among percentage positively stained of these three antibodies was significant, p-values was lower 0. 05. MECs were not found with immunohistochemistry in 170 of 384 duets (44. 27%)with anti-CD10,74 of 384 ducts(19.27%) with anti-SMA and 127 of 384 ducts(33.07%) with anti-P63. MECs were not found with CD10,SMA and P63 in 30 patients with breast invasive carcinomas. Conclusion We concluded that CDIO could be another useful marker of breast myoepithelial cells after SMA and P63. It provided more sophisticated information about presence or absence of breast myoepithelial cells in confusing breast lesions.

Objective To research the calcium dependent intercellular adhesion molecule (E-cadherin,E-cad)expression and the relationship between E-cad and growth patterns and CT manifestations of peripheral pulmonary carcinoma(PPC).Methods In this study,E-cad was tested by immunohistochemical SABC methed in 57 lung cancer specimens and,of which,the histologic study were made in the mass and lung-tumor interface of 33 resected specimens to detect the growth patterns.CT scan was obtained in all cases before operation.Results The results showed that the expresson levels of E-cad was lower in lung cancer specimens than those in adjacent normal lung tissues (?

Objective To observe the expression of CD_ 105 in breast cancer, and explore the correlation between CD_ 105 and growth, invasion and metabasis of breast cancer. Methods 50 cases of breast infiltrating duct cancer, 20 cases of breast duct cancer and 20 cases of breast benign hyperplasia were enrolled in this study. The microvascular density(MVD) was marked with CD_ 105 and F-8RAg using immunohistochemical S-P method. Results The expression level of CD_ 105 in breast infiltrating duct cancer was significantly higher than that in breast duct cancer and benign hyperplasisa(P

Objective To study the quantitative cytomorphologic parameters in early diagnosis and follow-up of lung cancer.Method With HE staining and image analysis,quantitative analysis of cytomorphology was made on paraffin sections of 86 specimens of bronchial mucosa,sampled by bronchoscopic biopsy,which would reflect a series of events from squamous metaplastic bronchial epithelium to invasive bronchogenic carcinoma.Result 8 nuclear parameters (area,deviation of area,perimeter,deviation of perimeter,shape factor,deviation of shape factor,volume density nucleus,nucleus/plasma ratio)and 2 cellular nodes(perimeter,deviation of perimeter)increased or decreased parallelly with advancing nuclear atypia.Conclusion The two stages of the moderate and severe atypical metaplasia of bronchial epithelium are the critical ones changing from benign to malignant.The quantitative analysis of cytomorphology is useful for discovering and following up the precancerous lesions of bronchogenic squamous cell carcinoma.

ObjectiveTo investigate the expression of T lymphocytes and activated subsets in patients with HIV/AIDS and early latent syphilis. MethodsT lymphocytes and activated subsets ( HLADR+ CD3 +/CD3 + , HLA-DR+ CD4 +/CD4 + and HLA-DR+ CD8 +/CD8 + ) as well as rapid plasma reagin (RPR) and treponema pallidum particle agglutination (TPPA) test were detected by flow cytometry in 78 patients with HIV/AIDS, 66 patients with HIV/AIDS and early latent syphilis, and 30 healthy subjects. SPSS 13.0 was used for statistical analysis, and t (for normal distribution) or Mann-Whitney U (for skew distribution) tests were performed to compare between the groups. ResultsThe absolute counts of CD4+ T cells in patients with HIV/AIDS and early latent syphilis were significantly higher than those in HIV/AIDS patients ( t = 2. 041 and 2. 223, P ＜ 0.05 ), but no difference in the counts of CD3 + T cells and CD8 + T cells was observed (tcD3 =0. 362 and 0.692, tcD8 =0.043 and 0.617, P＞0.05). HLA-DR+ CD4 +/CD4 +level in AIDS plus syphilis group was much higher than that in HIV plus syphilis group ( t = 2. 647, P ＜ 0. 05 ), but no difference was observed in HLA-DR+ CD3 +/CD3 + and HLA-DR+ CDs +/CDs + ( t = 1. 112 and 0. 093, P ＞ 0.05). ConclusionsImmune function in patients with HIV/AIDS and early latent syphilis may be enhanced temporarily.

To explore the differential expression of serum miRNAs in patients of advanced non- small cell lung cancer (NSCLC) treated by gifitinib before and after acquiring drug resistance.
 Methods: A total of 4 patients with advanced NSCLC from Affiliated Hospital of Yueyang Vocational Technical College, who acquired drug resistance during gefitinib therapy from June 2013 to June 2015, were enrolled. Serum samples were collected before treatment and after acquiring drug resistance. MicroRNA (miRNA) microarray was used to assess the levels and compositions of miRNAs in serum. Real-time RT-PCR was used to validate the results of miRNAs with significant differences in expression. The candidate miRNAs inhibitors and mimics were transfected into lung cancer cells by liposome, and the sensitivity of lung cancer cells to gifitinib was detected.
 Results: The miRNA microarray showed that there were significantly differential expression of miRNAs in serum of NSCLC patients after acquiring drug resistance, and 24 miRNAs were changed in more than 2-fold. Among them, 19 miRNAs were up-regulated and 5 miRNAs were down- regulated (both P<0.05). Especially, the expression of miR-21 in serum of NSCLC patients after obtaining resistance was up-regulated more than 10-fold compared with that before treatment. The results of RT-PCR was consistent with the results of miRNA microarray. The up-regulation of miR-21 in lung cancer cells could elevate the half maximal inhibition concentration (IC50) of gefitinib, and the down-regulation of miR-21 in lung cancer cells could reduce the IC50 of gefitinib (both P<0.05).
 Conclusion: There is differential expression of miRNAs in serum of NSCLC patients before treatment and after acquiring drug resistance during gefitinib therapy. The up-regulation of miR-21 may be involved in regulating the acquiring drug resistance of gefitinib.
Antineoplastic Agents ; pharmacology ; therapeutic use ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; drug effects ; genetics ; Gene Expression Regulation, Neoplastic ; drug effects ; Humans ; Lung Neoplasms ; drug therapy ; MicroRNAs ; blood ; genetics

Objective To discuss the application of self-developed novel 16-slice mobile CT head scan.Methods A total of 391 patients were performed 16-slice mobile CT scan:145 were scanned in the emergency department,156 in the neurosurgical ICU,55 in the operated room,and 35 in the ambulance vehicle.Sixty-eight patients were with brain injury,122 were with cerebral hemorrhage,120 were with cerebral infarction,59 were with brain tumors,and 22 were with hemifacial spasm.Thirty-five patients were randomly selected from 391 patients and 8-slice mobile CT head scan was performed on them,which included 12 with brain injury,6 with cerebral hemorrhage,12 with cerebral infarction,3 with brain tumors and 2 with hemifacial spasm.The resolution,imaging quality,radiation doses,power consumption and performance stability of novel 16-slice mobile CT and 8-slice mobile CT head scan were compared.Results The resolution line pairs of brain tissues were 91 p/cm by 16-slice mobile CT and 71 p/cm by 8-slice mobile CT,respectively.The imaging quality of the two kinds of mobile CT head scans was high level to the clinic diagnostic criteria.The radiation dose of 16-slice mobile CT were 40.43 mGy,which decreased by 51.01％ as compared with that of 8-slice mobile CT (82.52 mGy).The personal power consumption of 16-silce mobile CT (0.29 kW· h) decreased by 38.30％ as compared with those of 8-layer mobile CT (0.47 kW· h).The 16-slice mobile CT kept regularly,while 8-slicer mobile CT stopped to work twice during clinical trial.Conclusion The 16-slice mobile CT scan has high resolution,fine imaging quality,low radiation dose,small power consumption and stable working performance.

Objective: To investigate the expression of syndecan-1 and syndecan-2 and their clinicopathological significance in patients with gallbladder squamous cell (SC)/adenosquamous carcinoma (ASC) and adenocarcinoma (AC). Methods: A total of 126 patients with SC/ASC (n=46) and AC (n=80) were included in this study. The expression levels of syndecan-1 and syndecan-2 were detected by Envison™ immunohistochemistry assay. The clinical and prognostic significance of syndecan-1 and syndecan-2 were analyzed. Results: In the 46 SC/ASC samples, syndecan-1 and syndecan-2 were positively expressed in 29 (63.0%) and 28 (60.9%) tumor tissues, respectively. (Positive expression was defined based on the staining in the component of squamous cell carcinoma. That is to say, the tissue which adenocarcinoma part was positively stained, but squamous cell carcinoma part was negatively stained is also regarded as negative.) In the 80 AC samples, 47 (58.8%) cases showed syndecan-1 positive expression, and 51 (63.8%) showed syndecan-2 positive expression. There was no significant difference in the positive rates of syndecan-1 and syndecan-2 between SC/ASC and AC groups (P>0.05 for all). The levels of syndecan-1 and syndecan-2 were associated with tumor size, TNM staging, lymph node metastasis, invasion of adjacent tissue, and surgical procedures in SC/ASC patients (P<0.05 for all). However, their expression was associated with tumor differentiation, tumor size, TNM staging, lymph node metastasis, invasion of adjacent tissue, and surgical procedures in AC patients (P<0.05 for all). The Kaplan-Meier survival analysis of SC/ASC and AC patients revealed that the average survival time for patients with positive syndecan-1 and syndecan-2 expression was significantly shorter than that of those with negative expression (P<0.01 for all). Cox multivariate analysis indicated that syndecan-1 and syndecan-2 expression were independent unfavorable prognostic factors for SC/ASC and AC patients (P<0.05 for all). Conclusion The syndecan-1 and syndecan-2 expression are associated with the tumor progression and poor prognosis in patients with gallbladder SC/ASC and AC.